Essex Investment Management Co. LLC grew its stake in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 298.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,665 shares of the biotechnology company’s stock after buying an additional 52,184 shares during the quarter. Essex Investment Management Co. LLC owned 0.20% of Audentes Therapeutics worth $2,177,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. ProShare Advisors LLC grew its stake in shares of Audentes Therapeutics by 27.1% in the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 3,324 shares during the last quarter. SG Americas Securities LLC bought a new stake in Audentes Therapeutics during the 3rd quarter valued at approximately $143,000. Nationwide Fund Advisors boosted its position in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Audentes Therapeutics by 86.1% during the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 6,667 shares during the last quarter. Finally, Ardsley Advisory Partners lifted its holdings in shares of Audentes Therapeutics by 59.7% during the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after purchasing an additional 7,500 shares during the last quarter. 64.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) traded down $0.79 during mid-day trading on Wednesday, reaching $32.01. 154,300 shares of the company’s stock traded hands, compared to its average volume of 543,451. The stock has a market cap of $1,192.16, a PE ratio of -9.17 and a beta of 0.41. Audentes Therapeutics Inc has a 1-year low of $13.90 and a 1-year high of $41.80.
In related news, SVP Mary Newman sold 10,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $26.84, for a total value of $268,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,000 shares of company stock worth $1,052,480 over the last 90 days. Corporate insiders own 47.30% of the company’s stock.
Several equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Audentes Therapeutics in a report on Wednesday, February 7th. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 9th. William Blair initiated coverage on shares of Audentes Therapeutics in a report on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 price objective for the company. Mizuho initiated coverage on shares of Audentes Therapeutics in a research report on Monday. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Raymond James Financial reaffirmed a “hold” rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Audentes Therapeutics has an average rating of “Buy” and an average price target of $34.00.
COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics Inc (NASDAQ:BOLD) Shares Bought by Essex Investment Management Co. LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/essex-investment-management-co-llc-has-2-18-million-position-in-audentes-therapeutics-inc-bold.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.